Lupin Ltd Q2 FY2024 Concall Summary

Key Takeaways

• Margin promise delivered early: EBITDA margin hit ~18% in Q2, a target originally set for Q4, driven by a 170 bps sequential gross margin improvement and cost optimization.
• U.S. business finds a durable floor: Revenue sustained above \$200 mn for a fifth straight quarter, with respiratory products now contributing 45%+ of the mix and mid-single-digit price erosion stabilizing.
• The pipeline is loading for FY26: Approvals for gTolvaptan and gXywav, plus the Pithampur Unit 2 clearance, set the stage for a material step-up in complex generics, with management pointing to a potential \$250 mn quarterly U.S. run rate.
• Spiriva ramp is on track but inventory noise is coming: The Tiotropium launch is building toward a 35–40% share, yet some inventory correction is expected over the next couple of quarters as customer stocks sync with the substitution rate.
• What to watch next quarter: The pace of the Spiriva inventory correction, the initial contribution from Diastat and Nascobal launches, and any update on the Pegfilgrastim facility remediation submitted to the FDA by March.

U.S. Business: The Floor, The Ramp, and The Pipeline

• Base business stabilized: Inline products are stable to slightly growing, and price erosion on the baseline portfolio has settled at a mid-single-digit level that management hopes will persist.
• Respiratory dominance: Respiratory products now drive over 45% of U.S. revenues, with the Tiotropium (Spiriva) launch as the flagship. The ramp-up is tracking expectations: starting at a 20–25% share and building toward 35–40% over a year, with a current substitution rate of 25%.
• Spiriva inventory correction ahead: A pipeline fill effect from Q2 is carrying into Q3, but management expects some leveling off and inventory correction over the next couple of quarters as customer stocks synchronize with the substitution rate.
• HandiHaler decline flattens: The brand had been converting patients to Respimat via couponing, but the HandiHaler decline has flattened in recent months, a sign management calls promising for the overall molecule share.
• New launches stacking up: Darunavir launched in Q1 with an initial pipeline build, so Q2 levels were lower. Diastat launched last week, Nascobal is expected to launch next week, and both will contribute to growth in Q3 and Q4.
• FY26 as the breakout year: Management sees fiscal year '26 as a material step-up, with the Tiotropium ramp-up continuing, Tolvaptan launching, potentially Liraglutide (depending on litigation), and ophthalmic injectables ramping, pushing the quarterly U.S. run rate closer to \$250 mn.

Vinita Gupta: "Yes, actually we have seen our inline products pretty stable, growing a bit and the new product launches contributing as well."

Margin Recovery: Pulling the Levers Early

• Gross margin leads the charge: Gross margins improved 170 bps sequentially (ex-NCE), driven by a better product mix, a lower share of in-license products, commodity deflation, higher volumes, and cost improvement initiatives in freight and other areas.
• Employee cost optimization: Employee benefits expense as a percentage of sales fell due to cost optimization, partially offset by the field force expansion undertaken last year and other new initiatives.
• Other expenses contain one-offs: Other expenses rose ~26% YoY, but this includes one-time stamp duties and costs from the CDMO spin-off, plus provisions. Excluding these, the cost base should be closer to the 30% mark, and management expects to keep it on a leash around that level going forward.
• H2 margin target: Management expects to sustain around 18% EBITDA margin in both Q3 and Q4, having achieved the target two quarters early.
• Longer-term ambition: The goal is to close the gap with peers by reaching the mid-20s in profitability over the next few years, with a clear path to a good 20%+ first. Beyond five years, investment plans in specialty will determine the further trajectory.

Vinita Gupta: "On the last occasion that we met, we mentioned that we would strive to achieve around 18% EBITDA margin by Q4 of the current year. I am happy that we have delivered on our promise, in this quarter itself."

Pipeline & Complex Generics: The FY26 Inflection

• Key approvals secured: Generic Tolvaptan and generic Xywav were approved in October and are expected to drive a big part of growth in the next couple of years, with Tolvaptan described as a material product launching in fiscal year '26.
• Pithampur Unit 2 unlocks ophthalmics: The facility clearance enables 5–6 ophthalmic products (Bromday, Bromsite, Loteprednol, Prolensa) expected to reach the market over the second half of this fiscal year and next.
• Injectable cadence: Ganirelix and Famotidine are expected to launch this fiscal year; Glucagon, a material product, is slated for next fiscal year.
• First-to-file oral solids: Beyond Tolvaptan in FY26, Mirabegron, Oracea, and Doxycycline are expected to see approvals and litigation outcomes over the next couple of months, with launches in the next two years. Management prevailed on one major Mirabegron patent in district court (on appeal) and settled on another, but declined to share an actual launch date, saying only they are actively working on litigation strategy.
• Biosimilars and complex injectables: Pegfilgrastim facility received an EIR from the FDA with areas of improvement identified; an update to the agency is due by March. Ranibizumab has its last patient in, with filing about a year away. Risperdal Consta (long-acting Risperidone) is filing this month and hoped for market by FY26.
• Revlimid: Launch expected in fiscal year '26.

Non-U.S. Markets: Complex Generics Go Global

• Europe as a growth engine: Europe recorded strong growth driven by the ramp-up of generic Fostair in direct markets (UK, Germany) and through partners elsewhere in the EU; it has become the largest product in the region. Germany recorded its highest ever sales during the quarter.
• Canada and Australia momentum: Both have had a strong run rate over the last couple of quarters, and Tiotropium is expected to launch soon in both markets.
• Mid-teens compounding expected: Management expects Europe, Canada, and Australia to compound in the mid-teens, with the company under-indexed in ex-U.S. developed markets and the complex generic portfolio (inhalation, biosimilars, injectables) enabling growth.
• Five-year portfolio shift: Over the next five years, roughly two-thirds of the developed market portfolio is expected to switch to complex generics, making these geographies a larger part of the overall business.

India Business: Back to Growth in Diabetes

• Market-level growth with pockets of strength: India business grew in line with the market, with better-than-market performance in Cardiology, Respiratory, GI, and Women's health.
• Diabetes turnaround: The diabetes therapeutic area, previously in de-growth, has returned to growth. The non-in-licensed diabetes portfolio grew 10% versus an IPM category growth of 4.9%.
• Field force investment: The sales force expansion undertaken last year is expected to help build on the H1 growth rate; October was strong, and management expects that to continue in Q3 and Q4. The mid-to-long-term expectation is to grow better than the market.

Investments & Compliance: Building the Foundation

• R&D spend rising: Full-year R&D is expected around INR 1,500–1,600 crores, with the YoY increase driven by investment in newer platforms like biosimilars and injectables.
• Compliance commitment: Management is committed to ensuring all sites reach a consistent and sustainable level of compliance, with the Pithampur Unit 2 clearance and Pegfilgrastim EIR as recent markers of progress.
• ESG recognition: The company received an S&P Global CSA ESG score of 68, up from 46 last year and 17 in 2021, placing it at the 95th percentile of the global pharma industry.
• CDMO spin-off costs: One-time expenses, including stamp duties and other costs, were incurred during the quarter and are reflected in the elevated other expenses line.

Guidance & Commitments

Key Metrics